- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- Olopatadine HCl Nasal Spray, 0.6%, Azelastine HCl Nasal Spray, 0.1%
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 100
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Rhinitis, Allergic
- Interventions
- Chlorpheniramine maleate (BAY X002134), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Germantown, Tennessee
- Conditions
- IgM MGUS, Waldenstrom Macroglobulinemia, Neuropathy;Peripheral
- Interventions
- Acalabrutinib, Rituximab
- Drug
- Lead sponsor
- Shayna Sarosiek, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Sudden Cardiac Death
- Interventions
- Electrophysiology study (EPS), Standard Care, Cardiac Magnetic Resonance (CMR)
- Procedure · Other
- Lead sponsor
- Western Sydney Local Health District
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,058 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Adenocarcinoma
- Interventions
- Avelumab
- Drug
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Sacituzumab tirumotecan, Pemetrexed, Carboplatin, H1 Receptor Antagonist, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent)
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 17
- States / cities
- Oakland, California • Roseville, California • San Francisco, California + 13 more
- Conditions
- COVID-19
- Interventions
- Experimental: Primary Cohort, Placebo Comparator: Primary Cohort - Placebo
- Drug · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Allergic Rhinitis
- Interventions
- Loratadine (Claritin, BAY76-2211)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Teaneck, New Jersey
- Conditions
- Lupus Nephritis
- Interventions
- Rituximab, Cyclophosphamide, Prednisone, Methylprednisolone, Diphenhydramine, Acetaminophen, Belimumab
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- barzolvolimab, Matching placebo
- Biological
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 976 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 63
- States / cities
- Cullman, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 47 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- AK006 IV
- Drug
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Bakersfield, California • Upland, California + 6 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 505 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Kirksville, Missouri
- Conditions
- Gastroesophageal Cancer
- Interventions
- Sacituzumab tirumotecan, Trifluridine-Tipiracil, Irinotecan, Paclitaxel, Docetaxel, Rescue medications, Supportive care measures
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 17
- States / cities
- Gilbert, Arizona • Los Angeles, California • Orlando, Florida + 13 more
- Conditions
- Moderate or Severe Submental Fullness
- Interventions
- Deoxycholic Acid Injection, Placebo, Cold Compress, Lidocaine / Epinephrine, Loratadine, Ibuprofen, Compression Chin Strap
- Drug · Other
- Lead sponsor
- Kythera Biopharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Voice Disorder Due to Iatrogenic Factor
- Interventions
- Chlor-Trimeton.
- Drug
- Lead sponsor
- Auburn University
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Auburn, Alabama
- Conditions
- High Grade Glioma, Glioblastoma, Gliosarcoma
- Interventions
- Dexbrompheniramine, Temozolomide
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Pemphigus
- Interventions
- Ofatumumab, Acetaminophen/paracetamol, Antihistamine (cetirizine or equivalent), Prednisone/Prednisolone
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- Not listed
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Ann Arbor, Michigan
- Conditions
- Endometrial Cancer
- Interventions
- Sacituzumab tirumotecan, Doxorubicin, Paclitaxel, Nab-paclitaxel, Rescue medications
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 710 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 43
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 39 more
- Conditions
- Lung Cancer
- Interventions
- cetuximab
- Biological
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 157
- States / cities
- Aurora, Colorado • Colorado Springs, Colorado • Denver, Colorado + 107 more
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Pembrolizumab, I-DXd, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU), Oxaliplatin, Sacituzumab tirumotecan, Rescue Medication
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Advanced Solid Tumors, Malignant Neoplasm
- Interventions
- MK-2010, Sacituzumab tirumotecan, Histamine H1 Receptor Antagonist, Histamine H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid mouthwash (dexamethasone or equivalent), Epinephrine
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
- Interventions
- Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4
- Other · Drug
- Lead sponsor
- D. Walter Wray
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2030
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Lung Neoplasm Malignant
- Interventions
- MK-1084, Patritumab deruxtecan, Sacituzumab tirumotecan, Cetuximab, Rescue Medications
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 4
- States / cities
- Clermont, Florida • Chicago, Illinois • Portland, Oregon
- Conditions
- Asthma in Children
- Interventions
- Cholecalciferol, antihistamine, Azithromycin, emollient cream, Fluticasone Propionate, Asthma Controller Medication
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio